Ukraine alleges Russia missile attack on Indian pharma firm’s warehouse

Today, a Russian missile struck the warehouse of Indian pharmaceutical company Kusum in Ukraine.

While claiming “special friendship” with India, Moscow deliberately targets Indian businesses — destroying medicines meant for children and the elderly.#russiaIsATerroristState https://t.co/AW2JMKulst

— UKR Embassy in India (@UkrembInd) April 12, 2025

The warehouse, operated by Kusum Healthcare, reportedly housed medical supplies critical for humanitarian needs. Kyiv has not yet released details of casualties or damage, but condemned the strike as a violation of international norms.

Russia has not responded to the allegations.

Before Kyiv’s post, Britain’s ambassador to Ukraine Martin Harris reported the assault adding the attack was carried out by Russian drones, not a missile.

“This morning Russian drones completely destroyed a major pharmaceuticals warehouse in Kyiv, incinerating stocks of medicines needed by the elderly and children. Russia’s campaign of terror against Ukrainian civilians continues,” Martin said in a post on X.

Earlier today, Russia’s defence ministry has accused Ukraine of launching five attacks on Russian energy infrastructure within the past 24 hours, in what it claims is a violation of a US-brokered agreement to halt such strikes.

Last month, both countries reportedly agreed to a moratorium on targeting each other’s energy facilities. However, tensions remain high, with both sides repeatedly blaming the other for breaching the agreement.

India, which has maintained a neutral stance, has called for peace and an end to violence but has refrained from openly taking sides in the conflict.

What is Kusum?

As per it’s website, Kusum, owned by Indian businessman Rajiv Gupta, is a multinational group of pharmaceutical companies employing over 2,000 employees across Ukraine, India, Moldova, Kazakhstan, Uzbekistan, the Philippines, Myanmar, Mexico, and Kenya. The Kusum Group operates four modern manufacturing facilities—three in India and one in Ukraine—along with two in-house research centres.